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Summary The objective of this observational study was to compare the efficacy of
levetiracetam and topiramate during the first 15 days of add-on treatment in adults
with refractory partial epilepsy.
Two cohorts of patients with 3 simple or complex partial seizures with or without
secondary generalisation per month over an 8-week baseline period received levetir-
acetam or topiramate in two distinct phases, in addition to standard antiepileptic
treatment. During the first 15 days of the therapy, levetiracetam was added at the
dosage of 250 mg b.i.d. or topiramate at 25 mg o.i.d. Efficacy parameters included
number of seizure-free days (SFDs), mean and percent reduction in seizure frequency
(in general and by type), and number of seizure-free patients in the first 15 days of
treatment compared to last 15 days of the baseline period.
Sixty-one patients received levetiracetam and 61 topiramate. The general char-
acteristics of the two treatment groups were similar. The total number of SFDs during
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15 days before treatment was 637 with levetiracetam and 621 with topiramate; in the
15-day evaluation period the SFDs increased to 748 (17.4%) and 668 (7.6%), respec-
tively (ANOVA, p < 0.05). Twenty-six patients (42.6%) taking levetiracetam were
seizure free compared to 10 (16.4%) receiving topiramate (chi-square, p = 0.003).
This open-label non-controlled study suggests an early efficacy of levetiracetam as
add-on therapy in patients with refractory partial epilepsy: these results appear to
confirm previous indications of a rapid onset of action and seem to suggest first
evaluation of the patient at the dose of 500 mg/day before increasing to the
considered minimum standard dose of 1000 mg/day, as some patients could respond
to the starting dose.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Epilepsy is one of the most common neurological
disorders, affecting up to 1% of the worldwide
population.1 Despite the large number of antiepi-
leptic drugs available, about 30% of patients still
have uncontrolled epilepsy.2 Levetiracetam is a
novel antiepileptic drug with a unique preclinical
profile,3 a favourable pharmacokinetic profile4 but
an as yet unclear mechanism of action,5 although a
brain-binding site in synaptic vesicle protein SV2A
has been recently proposed.6 Levetiracetam has a
high therapeutic index and a fairly wide safety
margin compared with other antiepileptic drugs.7
Results from phase II clinical trials evaluating leve-
tiracetam as add-on therapy in patients with refrac-
tory partial and/or secondary generalized seizures
demonstrated that doses up to 4000 mg/day are
effective and well tolerated.8,9 The efficacy and
tolerability of levetiracetam were confirmed in
phase III placebo-controlled studies, in which
patients with refractory partial epilepsy received
the drug at doses of 1000, 2000, or 3000 mg/day as
adjunctive or single treatment.10—12 Analysis of
pooled data showed a significant gain in seizure-
free days (SFDs) in patients on levetiracetam com-
pared to placebo.13 Both titration and study periods
were included in the analysis. In preclinical studies a
significant reduction in weekly seizure frequency
was observed over the first 2 weeks of the titration
period in patients taking levetiracetam, suggesting
a fast clinical effect of the drug since the initial
dose.12,14
Further investigation on the rapid onset of action
during the titration phase in three clinical trials
showed levetiracetam (1000 mg/day) significantly
increasing the mean proportion of seizure-free days
1, 2 and 3 days after the first dose intake.15
We conducted an observational study to investi-
gate the seizure outcome during the first 15 days at
the initial dose of the add-on treatment with leve-
tiracetam as compared to topiramate in adult
patients affected by refractory partial epilepsy.Methods
Study design
This was a single centre, prospective, observational,
add-on study. The study was conducted in two dis-
tinct phases: (a) baseline: 8-week period; (b) study
phase: 15-day add-on therapy with levetiracetam or
topiramate, each given as part of a separate pro-
spective observational study. As topiramate was
available in the market before levetiracetam, all
topiramate patients were recruited first. The titra-
tion policy was part of the usual management of the
two drugs in the centre’s clinical practice (see
below). Seizure counts were obtained from patients’
diaries according to the centre’s standard policy.
Levetiracetam was administered at a dose of
250 mg b.i.d., and topiramate 25 mg in single dose
(patients taking an enzyme-inducing drug had as
first dose of topiramate 50 mg in single dose).
During each phase concomitant antiepileptic
drug (AED) regimens remained unchanged; no other
medications were allowed during the study.
Patients were seen in three separate occasions:
baseline visit (8 weeks before the beginning of
treatment), recruitment visit (beginning of treat-
ment), final visit (15 days after the beginning of
treatment). A detailed record of seizures and of any
adverse events was available for all patients during
baseline and study periods.
Study population
Patients aged 16—60 years with refractory partial
epilepsy including simple and complex partial sei-
zures with or without secondary generalisation were
eligible.
To be selected, patients had to have a mean
monthly seizure frequency 3 during the baseline
period; their treatment could include up to two
other AEDs.
Patients were excluded if they had a progressive
neurological disease, severe psychiatric disorder,
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abnormalities. Pregnant or lactating women were
also excluded.
Efficacy and tolerability assessment
Efficacy was assessed by three parameters evalu-
ated in two matched periods: the 15-day treatment
phase and the 15-day period before starting add-on
treatment:a) TTa
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baotal number of seizure-free days;
b) Mean and percent reduction in seizure fre-
quency, in general and by seizure type;
c) Number of seizure-free patients.ble 1 Patients characteristics
Lev
mber of patients 61
e (years), mean  S.D. (range) 39.
x
Female 37
Male 24
ilepsy duration (years), mean  S.D. 27.
e at onset (years), median (range) 8
pe of epilepsy
Cryptogenic 30
Remote symptomatic 31
izure type
Partial 45
Secondary generalized 14
mber of AEDs mean (range)^ 4.
mber of AEDs at entry
1 33
2 28
CBZ 38
LTG 14
TPM 9
VPA 7
PHT 7
PB 6
CLB 4
FBM 2
GBP 1
OXC 1
VGB 1
TGB 1
CNP —
fferences of all patient characteristics are not significant at Stude
ned-rank test (age at onset, number of seizures in previous 15 da
Ds at entry). S.D. = standard deviation; ^ Overall (previous and c
ate; VPA = valproate; PHT = phenytoin; CLB = clobazam; FBM = fe
trin; TGB = tiagabine; CNP = clonazepam.A seizure-free day (SFD) was defined as a day
without any seizures. Markowitz et al.16 have argued
that this parameter includes both seizure frequency
and seizure severity and best reflects the patient’s
quality of life.
Tolerability was assessed by recording adverse
events, physical and neurological examination.
Statistical analysis
Student’s t-test, Wilcoxon’s signed-rank test, chi-
square test for heterogeneity and trend (Cochran-
Mantel-Haenszel), and ANOVA (for repeated mea-
sures) were used where appropriate. Differences
between treatment groups were expressed asmeansetiracetam Topiramate
61
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nt t-test (age, epilepsy duration, number of AEDs), Wilcoxon’s
ys), chi-square test (sex, type of epilepsy, seizure type, number
urrent). CBZ = carbamazepine; LTG = lamotrigine; TPM = topir-
lbamate; GBP = gabapentin; OXC = oxcarbazepine; VGB = viga-
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Table 2 Cumulative and mean number of seizures by type and treatment, comparing the two 15-day periods before
and after treatment start
Levetiracetam (n = 61) Topiramate (n = 61) P-value
Before After Percent
difference
Before After Percent
difference
Total number
of sz
787 624 20.7 687 576 16.2 0.47 *
Partial 744 602 19.1 581 503 13.4 0.41 *
PSG 43 22 48.8 106 73 31.1 0.33 *
Mean number
of sz (S.D.)
Total 12.9 (34.0) 10.2 (31.8) 11.3 (25.5) 9.4 (21.5) 0.81 **
Partial 13.2 (35.5) 10.4 (32.6) 13.4 (30.1) 11.3 (24.9) 0.94 **
PSG 4.2 (5.0) 2.9 (4.6) 1.4 (2.2) 0.7 (1.7) 0.01 **
Sz = seizures; PSG = partial secondary generalized; S.D. = standard deviation.
* Chi-square.
** ANOVA (repeated measures).with standard deviations (S.D.), in percent or, where
indicated, as odds ratios (OR) with 95% confidence
intervals (95% CI).
The association between seizure freedom and
study drug over the 15 days was also assessed using
a multivariate analysis model (logistic regression),
adjusting for age, sex, age at onset of seizures,
epilepsy duration, number of drugs at admission
and seizures in the preceding 15 days.Results
A total of 122 patients (74 women, 48 men) were
enrolled; 61 patients in the levetiracetam group and
61 in the topiramate group. Demographic and clin-
ical features did not differ between the two groups
(Table 1). All patients had long-lasting epilepsy, had
received 2—9 AEDs, and had high seizure frequency
at the baseline visit.
SFDs were 637 before treatment and 748 after
treatment with levetiracetam (difference 17.4%)
and 621 before treatment and 668 after treatment
with topiramate (difference 7.6%) (chi-square test,
p = 0.26). Themean (S.D.) number of SFDs increased
from 10.4 (4.5) to 12.3 (4.1) with levetiracetam and
from 10.2 (4.2) to 10.9 (4.4) with topiramate
(ANOVA, p = 0.29). During the 15 days before the
beginning of the new treatment, the median num-
ber of seizure was 4 (range 0—239) in the levetir-
acetam group and 5 (range 0—182) in the topiramate
group (Wilcoxon’s signed-rank test, p = 0.38). Dur-
ing the 15-day add-on treatment the median num-
ber of seizure was, respectively, 1 (range 0—177)
and 3 (range 0—144) (Wilcoxon’s signed-rank test,
p = 0.01). The cumulative and mean number of
seizures varied significantly by type, but, exceptfor secondary generalized seizures, non-significant
differences were found when comparing the two
treatments within each seizure category (Table 2).
Twenty-six patients (42.6%) receiving levetirace-
tam were seizure-free compared to 10 (16.4%)
receiving topiramate (chi-square test, p = 0.003).
The numbers for partial seizures were 17 (37.8%)
versus 6 (15.4%) (chi-square test, p = 0.02) and
those for secondary generalized seizures were 8
(50.0%) versus 7 (29.2%) (chi-square test, p = 0.16).
Logistic regression analysis showed that, over the
initial 15-day treatment period, treatment with
levetiracetam resulted in a larger number of sei-
zure-free patients than treatment with topiramate
(OR: 3.6; 95% CI: 1.5—8.8).
Adverse events were reported by nine patients
taking levetiracetam (somnolence 3, nervousness 3,
nausea 1, insomnia 1, dizziness 1) and in eight
patients taking topiramate (dizziness 2, nervousness
2, somnolence 2, paresthesia 1, diplopia 1). In all
patients the adverse events were mild and transient
and it was not necessary to stop the treatment.Discussion
The possibility of a rapid onset of action of levetir-
acetam has been suggested in open-label and pla-
cebo-controlled studies,10—12 and in the analysis of
the pooled data from placebo-controlled studies.14
Our study confirmed the rapid onset of action of
levetiracetam compared to topiramate, as adjunc-
tive therapy in patients with drug resistant partial
epilepsy seen in clinical practice.
The results of the study indicate that adjunctive
therapy with levetiracetam 500 mg/day appears
more effective than topiramate 25 mg/day in pro-
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of seizure freedom, and reducing seizure frequency
during the first 15 days of treatment. SFDs increased
by 17.4% in the levetiracetam group and by 7.6% in
the topiramate group; seizure-free patients were
42.6% and 16.4%, respectively.
We have no explanation of the rapid onset on
action of levetiracetam. Even if our study conclusion
is that the treatment with levetiracetam could be
effective from the starting dose, the study has
several limitations:- the non-randomized, observational study design
implies that this can only be an exploratory com-
parison of the efficacy of the two drugs; the
majority of the patients treated with levetirace-
tam were different from those taking topiramate
and the drugs were given in different periods;- the effects of the daily doses used here, which are
only the starting doses, may not apply to the
maintenance doses of the two drugs and to any
other dose changes, as usually done in clinical
practice.
Rapid onset of action does not indicate per se
long-term levetiracetam superiority.
Levetiracetam and topiramate showed a good
tolerability profile in the first 15 days of treatment
as adverse events were mild and transient and no
patients discontinued the treatment.
In conclusion, our results appear to confirm pre-
vious indications of a rapid onset of action of leve-
tiracetam and seem to suggest a first evaluation of
the patient at the dose of 500 mg/day before
increasing to the minimum optimised dose of
1000 mg/day, as some patients could respond to
the starting dose. This could be also relevant in
all cases for which a rapid action is required by
particularly severe clinical conditions.References
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